Rochester, NY 8/31/2009 4:29:39 PM
Achillion Pharmaceuticals, Inc. ACHN, Up 1.07% at the end the day
Achillion Pharmaceuticals, Inc.
Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases, released trading at 1.97 and gained trading at 1.89 but have not gained any volume shares.
As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Last Trade: 1.89
Day's Range: 1.78 - 1.99
52wk Range: 0.65 - 2.62
Change: +0.02 (1.07%)
Volume: 0.00
Avg Vol (3m): 28,000.00
About Achillion Pharmaceuticals, Inc
Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases. Within the anti-infective market, it focuses on the development of antivirals for the treatment of chronic hepatitis C and the development of antibacterials for the treatment of resistant bacterial infections. As of December 31, 2008, Achillion focused its efforts on advancing two late-stage preclinical candidates: ACH-1095, an NS4A antagonist for the treatment of chronic hepatitis C, being developed in collaboration with Gilead Sciences, Inc. (Gilead), and ACH-1625, a protease inhibitor also for the treatment of chronic hepatitis C. It has a pipeline of other product candidates, for which it is seeking appropriate collaborative partners. These product candidates include elvucitabine for the treatment of human immunodeficiency virus (HIV) infection and ACH-702 for the treatment of serious bacterial infections.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Disclaimer: Full disclaimer at http://StockEinsteain.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinsteain, nor any of its affiliates are registered investment advisors or broker dealers.
